US FDA Assesses Over 500 Biopharma Plants Remotely Via Records Review; Refines Process
Executive Summary
Agency may share outcomes of remote record reviews in lieu of inspections at US and foreign facilities.
You may also be interested in...
How The US FDA Honed Remote Tools To Assess Facilities During COVID Inspection Hiatus
FDA officials outline the impact of using alternative tools to assess manufacturing facilities amid COVID-19 and share key experiences around these, including with remote interactive evaluations.
How The US FDA Honed Remote Tools To Assess Facilities During COVID Inspection Hiatus
FDA officials outline the impact of using alternative tools to assess manufacturing facilities amid COVID-19 and share key experiences around these, including with remote interactive evaluations.
Fewer Observations, Shift In Emphasis Seen In FDA's Pandemic-Reduced Inspections
US agency mostly saw less of the same when it scaled back inspectional activity during COVID-19, but observed more training and equipment issues.